Early Access — free while we kick the tires
EdgarHawk

FDMT 4D Molecular Therapeutics, Inc. Insider Trading

Latest: Officer & Director Sold $1.2M of Shares · Jun 2026
1 filing analyzed · Latest 2026-06-23
Insider buys
0
Insider sells
1
Unique insiders
1
Direction
Net selling

Historically, stocks have lagged the S&P 500 by a median ~3% over the 90 days after a medium insider sell (n ≈ 11,161, 2023-2026). Past results don't predict the future. How we measure this ↗

June 2026
2026-06-23
medium
David Kirn Sell
See Remarks
114,746 shares
$1,200,851
@ $10.47
Significance 4/10

David Kirn sold 114,746 shares of FDMT at $10.47 under pre-arranged 10b5-1 plan; retains 942,485 shares.

David Kirn executed a scheduled sale of 114,746 shares at $10.47 on 2026-06-22 under a 10b5-1 trading plan adopted on 2026-01-09, reducing his holdings by 10.9% to 942,485 shares. The stock currently trades at $11.60, down 6.0% from its 52-week high of $12.34. His prior five trades at FDMT have shown mixed near-term outcomes (30-day returns ranging from -13.9% to +9.0%) but consistently positive 90-day returns, with the most recent pre-2026 sale in February 2024 followed by a 90-day gain of +73.8%. The company remains unprofitable with a net income of $-68,760,000.00 on quarterly revenue of $3,047,000.00, indicating a pre-revenue stage enterprise despite recent annual revenue growth of +230194.6%. This is a scheduled transaction, not a discretionary signal of confidence or concern.

Get alerts for FDMT

Add FDMT to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access